Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

o show," "can," "to report," "to affirm," "will," "may," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets has announced ... X-ray Film Industry Report 2014" report to their ... Global And Chinese Medical X-Ray Film Industry Report ... current state of the Global medical X-ray film industry ... report provides a basic overview of the industry including ...
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Needles Market 2014-2018" report to their offering. ... hypodermic needle is a hollow needle commonly used with ... or to extract fluids from it. A hypodermic needle ... inject substances that cannot be ingested. Hypodermic needles are ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3
... Oct. 13, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in ... of a Multicenter Phase l/2 Trial" reporting Phase ... the treatment of advanced multiple myeloma (MM) patients, was ...
... PALO ALTO, Calif., Oct. 13, 2011 Telik, Inc. ... of a Phase 2b clinical trial to evaluate Telintra ... transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have ... Vidaza® or Dacogen®.  This patient population represents the majority ...
Cached Medicine Technology:Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 2Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 3Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology 4Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 2Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome 3
(Date:7/12/2014)... rise in the number of mobility devices around the ... suit the upsurge. Virtualization has become a growing trend ... The data traffic has increased by several folds with ... in larger and more complex networks. These global factors ... , The North American (NA) region is expected to ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
Breaking Medicine News(10 mins):Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4
... early childhood exposures to industrial chemicals in the environment ... neurodevelopmental disorders (NDDs)—autism,// attention deficit disorder (ADHD), and mental ... identify the individual chemicals that can cause injury to ... new review study, published in the print issue of ...
... treating common ear infections in children with ear tubes ... antibiotic ear drops over antibiotics swallowed// in pill or ... Center researcher reports. ,The latest study, involving ... and faster in treating middle ear infections in children ...
... publication in the Journal of Clinical Endocrinology and ... provided by The Hormone Foundation, the public education ... Lifestyle Accelerates Testosterone Decline ... but a new study confirms that many health ...
... certain vitamins, in order to reach out to the needful ... to be made a compulsion in bread would prevent neural ... prove to be harmful towards older people as folic acid ... and nervous problems in the long run. ,The pain ...
... as one of the toughest and most strenuous jobs. A ... the workload// and strain makes them sick. ,The ... nearly 19,000 nurses, which included registered nurses, licensed practical nurses ... that nurses face a variety of physical and emotional challenges ...
... will soon be reaching out to hundreds of people ... and support//. ,The US-based AIDS Healthcare Foundation (AHF) ... in Assam's main city of Guwahati, the eastern town ... ,India's National AIDS Control Organisation (NACO) and ...
Cached Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:Antibiotic Ear Drops Favored Over Oral Antibiotics for Ear Infections 2Health News:Testosterone Decline in Men Linked to Lifestyle, Increases in Obese Girls 2Health News:Folic Acid Supplementation in Bread: Boon to Neonates and Curse to Pensioners 2Health News:US NGO to Counsel HIV/AIDS Patients in Assam 2
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Only Mentors reusable Alpine Leg Bag has patented Kraylex odor barrier, offset port options, and integrated loops providing total confidence and comfort....
Medicine Products: